Umbralisib 200 mg Oral Tablet
RxNorm 2478444

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2478444 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: umbralisib 200 mg Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
Umbralisib 200 mg Oral Tablet
Primary clinical definition
AUI:12539165
View
FN
Product containing precisely umbralisib (as umbralisib tosylate) 200 mg/1 each conventional release oral tablet (clinical drug)
AUI:12666119
View
PT
Umbralisib (as umbralisib tosylate) 200 mg oral tablet
AUI:12666374
View
PSN
Umbralisib 200 mg Oral Tablet
AUI:12539177
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCD

Semantic Clinical Drug (SCD):
Umbralisib 200 mg Oral Tablet
(Atom ID: 12539165)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
umbralisib 200 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2478444
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12539165
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
2478444
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2478440} 2478438
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2478440} 2478439
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2478440} AM
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXTERM FORM
Tab
The RxTerm dose form name for this drug
FN

Full form of descriptor (FN):
Product containing precisely umbralisib (as umbralisib tosylate) 200 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 12666119)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing precisely umbralisib (as umbralisib tosylate) 200 milligram/1 each conventional release oral tablet (clinical drug)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2478444
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12666119
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
1148717005
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
PT

Designated preferred name (PT):
Umbralisib (as umbralisib tosylate) 200 mg oral tablet
(Atom ID: 12666374)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Umbralisib (as umbralisib tosylate) 200 mg oral tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2478444
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12666374
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
1148717005
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
PSN

Prescribable Name (PSN):
Umbralisib 200 mg Oral Tablet
(Atom ID: 12539177)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
umbralisib 200 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2478444
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12539177
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2478444
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Umbralisib


Umbralisib is used to treat marginal zone lymphoma (MZL; a slow growing cancer that begins in a type of white blood cells that normally fight infection) in adults whose cancer has returned or did not respond to a certain type of medication. It is also used to treat follicular lymphoma (FL; a type of cancer that begins in the white blood cells) in adults whose cancer has returned or did not respond to at least three other medications. Umbralisib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
[Learn More]


* Please review the disclaimer below.